- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Timothy I. Still
Chairman
Timothy is the Chairman of the Board of Directors at Volition, with over 35 years’ experience in medical diagnostics, devices and digital health.
Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development strategies within both large and small companies. Tim has been directly responsible for building the commercial viability at his previous companies, many through to acquisition.
His most recent operating role was President and CEO of Sense Biodetection. Early in 2023, Sense Bio merged with Sherlock Biosciences to create a leading point of care diagnostics company serving the consumer diagnostics market. Prior to Sense Biodetection, Mr. Still has been a CEO and/or a board member at numerous medical technology companies: Myoscience, MDx Health, Gold Standard Diagnostics (Executive Chairman), Global Kinetics, Xagenic and Accumetrics. Earlier in his career, Tim also held senior leadership roles at HemoSense, Cholestech, and Boehringer Mannheim / Roche.
Mr. Still has a master’s degree in business administration (Dean’s Scholar) from the University of Southern California, and a Bachelor of Science degree (Highest Honors) from the University of California at Davis.
“With its ground breaking epigenetic technology, I believe Volition has the potential to significantly impact global healthcare by detecting, guiding treatment, and monitoring disease, to improve outcomes for people and animals worldwide.”
Timothy Still
Chairman